What is Jasper Therapeutics Inc's earnings per share (EPS)?

Jasper Therapeutics Inc (JSPR) reported diluted earnings per share of $-3.95 for fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jasper Therapeutics Inc Financials

JSPR

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Jasper Therapeutics Inc (JSPR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

0/9

Jasper Therapeutics Inc passes 0 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.02x

For every $1 of reported earnings, Jasper Therapeutics Inc generates $1.02 in operating cash flow (-$77.2M OCF vs -$75.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$82.8M

YoY-10.6%

Jasper Therapeutics Inc's EBITDA was -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.6% from the prior year.

Net Income

-$75.8M

YoY-6.4%

Jasper Therapeutics Inc reported -$75.8M in net income in fiscal year 2025. This represents a decrease of 6.4% from the prior year.

EPS (Diluted)

$-3.95

YoY+19.2%

Jasper Therapeutics Inc earned $-3.95 per diluted share (EPS) in fiscal year 2025. This represents an increase of 19.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$28.7M

YoY-59.9%

5Y CAGR+7.7%

Jasper Therapeutics Inc held $28.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

28M

YoY+86.4%

Jasper Therapeutics Inc had 28M shares outstanding in fiscal year 2025. This represents an increase of 86.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-1826.1%

YoY-1710.5pp

Jasper Therapeutics Inc's ROE was -1826.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1710.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$63.1M

YoY+13.0%

5Y CAGR+31.8%

Jasper Therapeutics Inc invested $63.1M in research and development in fiscal year 2025. This represents an increase of 13.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

JSPR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$6.7M	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$63.1M+13.0%	$55.8M+7.8%	$51.8M+49.6%	$34.6M+36.2%	$25.4M+60.1%	$15.9M
SG&A Expenses	$20.8M+1.8%	$20.4M+19.6%	$17.1M+3.1%	$16.6M+45.2%	$11.4M+137.8%	$4.8M
Operating Income	-$83.9M-10.0%	-$76.2M-10.7%	-$68.9M-34.5%	-$51.2M-39.0%	-$36.8M-78.1%	-$20.7M
Interest Expense	N/A	N/A	-$246K-113.9%	-$115K-43.8%	-$80K+27.9%	-$111K
Income Tax	$2K0.0%	$2K0.0%	$2K	N/A	N/A	$38K
Net Income	-$75.8M-6.4%	-$71.3M-10.6%	-$64.5M-71.1%	-$37.7M-23.0%	-$30.6M+3.3%	-$31.7M
EPS (Diluted)	$-3.95+19.2%	$-4.89+20.9%	$-6.18+40.2%	$-10.33	$-2.69	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$9.3M	N/A	N/A	N/A	$8.8M	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$14.4M-32.1%	$21.2M+31.2%	$16.2M	N/A	$14.5M+28.0%	$11.3M+9.7%	$10.3M	N/A
SG&A Expenses	$4.8M-18.8%	$5.9M+4.2%	$5.6M	N/A	$5.4M+15.7%	$4.7M-1.6%	$4.8M	N/A
Operating Income	-$19.2M+29.2%	-$27.1M-24.2%	-$21.8M	N/A	-$19.9M-24.4%	-$16.0M-6.1%	-$15.1M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$18.7M+29.9%	-$26.7M-25.8%	-$21.2M	N/A	-$18.6M-27.8%	-$14.6M-6.2%	-$13.7M	N/A
EPS (Diluted)	$-1.13+35.1%	$-1.74-23.4%	$-1.41	N/A	$-1.24-27.8%	$-0.97+5.8%	$-1.03	N/A

JSPR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$35.8M-55.2%	$79.9M-15.8%	$94.9M+96.2%	$48.4M-48.4%	$93.7M+301.0%	$23.4M
Current Assets	$34.6M-54.3%	$75.8M-14.8%	$88.9M+113.1%	$41.7M-52.5%	$87.8M+324.6%	$20.7M
Cash & Equivalents	$28.7M-59.9%	$71.6M-17.6%	$86.9M+127.2%	$38.3M-54.8%	$84.7M+327.0%	$19.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$31.6M+73.5%	$18.2M+10.8%	$16.5M+33.0%	$12.4M-48.7%	$24.1M-58.7%	$58.5M
Current Liabilities	$13.2M-13.4%	$15.2M+23.1%	$12.4M+75.1%	$7.1M-11.9%	$8.0M+99.9%	$4.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.2M-93.3%	$61.7M-21.4%	$78.4M+118.0%	$36.0M-48.2%	$69.5M+297.9%	-$35.1M
Retained Earnings	-$316.7M-31.5%	-$240.9M-42.0%	-$169.6M-61.3%	-$105.1M-55.9%	-$67.5M-83.2%	-$36.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$57.5M+23.7%	$46.5M-19.3%	$57.6M-27.9%	$79.9M-19.6%	$99.4M-12.7%	$113.9M-9.6%	$126.0M+32.7%	$94.9M
Current Assets	$54.6M+27.0%	$43.0M-19.2%	$53.2M-29.9%	$75.8M-20.0%	$94.8M-12.8%	$108.7M-9.7%	$120.3M+35.3%	$88.9M
Cash & Equivalents	$50.9M+28.8%	$39.5M-19.0%	$48.8M-31.9%	$71.6M-22.6%	$92.5M-13.4%	$106.8M-9.8%	$118.5M+36.4%	$86.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$45.9M+99.9%	$23.0M+49.6%	$15.4M-15.8%	$18.2M+15.8%	$15.7M+15.5%	$13.6M+7.0%	$12.7M-22.6%	$16.5M
Current Liabilities	$21.0M+2.6%	$20.5M+66.2%	$12.3M-19.1%	$15.2M+22.3%	$12.5M+23.7%	$10.1M+12.9%	$8.9M-27.9%	$12.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$11.6M-50.8%	$23.5M-44.4%	$42.2M-31.5%	$61.7M-26.3%	$83.7M-16.6%	$100.3M-11.4%	$113.2M+44.4%	$78.4M
Retained Earnings	-$307.6M-6.5%	-$288.8M-10.2%	-$262.1M-8.8%	-$240.9M-11.2%	-$216.5M-9.4%	-$197.9M-8.0%	-$183.3M-8.1%	-$169.6M

JSPR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$77.2M-23.3%	-$62.6M-20.2%	-$52.1M-13.5%	-$45.9M-36.2%	-$33.7M-84.4%	-$18.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$5K+100.9%	-$532K-99.3%	-$267K+53.6%	-$576K+76.3%	-$2.4M-1324.1%	$198K
Financing Cash Flow	$34.2M-28.6%	$47.9M-52.6%	$101.0M+183483.6%	$55K-99.9%	$101.0M+794.6%	$11.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$17.0M-10.0%	-$15.5M+32.3%	-$22.8M-8.1%	-$21.1M-50.4%	-$14.1M-20.3%	-$11.7M+25.8%	-$15.7M+4.5%	-$16.5M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0-100.0%	$1K-75.0%	$4K+105.3%	-$76K+72.3%	-$274K-74.5%	-$157K-528.0%	-$25K+89.1%	-$230K
Financing Cash Flow	$28.4M	N/A	N/A	$345K+3733.3%	$9K-95.0%	$181K-99.6%	$47.3M+17572.0%	-$271K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

JSPR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-1826.1%-1710.5pp	-115.6%-33.4pp	-82.2%+22.5pp	-104.7%-60.6pp	-44.1%	N/A
Return on Assets	-211.9%-122.7pp	-89.2%-21.3pp	-67.9%+10.0pp	-77.9%-45.2pp	-32.7%+102.9pp	-135.6%
Current Ratio	2.62-2.4	4.98-2.2	7.19+1.3	5.91-5.0	10.95+5.8	5.16
Debt-to-Equity	7.62+7.3	0.30+0.1	0.21-0.1	0.340.0	0.35+2.0	-1.66
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-161.9%-48.2pp	-113.7%-63.4pp	-50.3%	N/A	-22.3%-7.7pp	-14.5%-2.4pp	-12.1%	N/A
Return on Assets	-32.6%+24.9pp	-57.5%-20.6pp	-36.9%	N/A	-18.8%-5.9pp	-12.8%-1.9pp	-10.9%	N/A
Current Ratio	2.59+0.5	2.10-2.2	4.31-0.7	4.98-2.6	7.61-3.2	10.79-2.7	13.49+6.3	7.19
Debt-to-Equity	3.97+3.0	0.98+0.6	0.36+0.1	0.30+0.1	0.19+0.1	0.14+0.0	0.11-0.1	0.21
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

LAVA Therapeutics N.V. LVTX

$45.8M

Estrella Immunopharma ESLA

$44.8M

PepGen Inc PEPG

$119.6M

Lantern Pharma Inc LTRN

$18.2M

Klotho Neurosciences, Inc. KLTO

$56.7M

Frequently Asked Questions

Is Jasper Therapeutics Inc profitable?

No, Jasper Therapeutics Inc (JSPR) reported a net income of -$75.8M in fiscal year 2025.

What is Jasper Therapeutics Inc's EBITDA?

Jasper Therapeutics Inc (JSPR) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Jasper Therapeutics Inc's return on equity (ROE)?

Jasper Therapeutics Inc (JSPR) has a return on equity of -1826.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Jasper Therapeutics Inc's operating cash flow?

Jasper Therapeutics Inc (JSPR) generated -$77.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Jasper Therapeutics Inc's total assets?

Jasper Therapeutics Inc (JSPR) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Jasper Therapeutics Inc spend on research and development?

Jasper Therapeutics Inc (JSPR) invested $63.1M in research and development during fiscal year 2025.

How many shares does Jasper Therapeutics Inc have outstanding?

Jasper Therapeutics Inc (JSPR) had 28M shares outstanding as of fiscal year 2025.

What is Jasper Therapeutics Inc's current ratio?

Jasper Therapeutics Inc (JSPR) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.

What is Jasper Therapeutics Inc's debt-to-equity ratio?

Jasper Therapeutics Inc (JSPR) had a debt-to-equity ratio of 7.62 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jasper Therapeutics Inc's return on assets (ROA)?

Jasper Therapeutics Inc (JSPR) had a return on assets of -211.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jasper Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Jasper Therapeutics Inc (JSPR) had $28.7M in cash against an annual operating cash burn of $77.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Jasper Therapeutics Inc's Piotroski F-Score?

Jasper Therapeutics Inc (JSPR) has a Piotroski F-Score of 0 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jasper Therapeutics Inc's earnings high quality?

Jasper Therapeutics Inc (JSPR) has an earnings quality ratio of 1.02x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.